Cinoxacin
Severe
Database
Drug interaction classified as: antagonism
Source: DDInter
Drug reference
Insulin Detemir
Long-acting basal insulin analogue · Antidiabetic, Insulin Therapy
START
10 units (or 0.1–0.2 U/kg) SC once daily
TYPICAL MAX
Titrated to target (no fixed ceiling)
STOP IF
Recurrent severe hypoglycaemia (reassess regimen)
WATCH
Fasting glucose, hypoglycaemia, weight, potassium
CDSCO approvedATC A10AE05
KDIGO 2024 + manufacturer label
- ONSET
- 1.5h · onset
- PEAK
- 7h · broad plateau
- t½
- 6h · t½ (apparent)
- DURATION
- 20h · basal cover
EXCRETION
Catabolised; minimal intact renal
route + CYP
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Acceptable in pregnancy (data support use; individualise).
FDA category + note
Top interactionssee all 12 →
- CinoxacinSevereDatabaseDDInter
- CiprofloxacinSevereDatabaseDDInter
- DelafloxacinSevereDatabaseDDInter
- EnoxacinSevereDatabaseDDInter
Available in India
1 branded formulation. Look up specific brands in the Drugs workspace.
Mechanism
Acylated insulin analogue that self-associates and reversibly binds albumin, producing a prolonged, relatively flat basal action via insulin-receptor agonism (glucose uptake, suppressed hepatic output).
Indications
Type 1 diabetes mellitus (basal insulin)Type 2 diabetes mellitus requiring basal insulin
Dosing
- Adult
- Start ~0.1–0.2 units/kg (or 10 units) once daily, or BID; titrate to fasting glucose target.
- Pediatric
- ≥1 y: individualised weight-based basal dosing.
- Renal adjustment
- No fixed reduction; insulin requirements often fall — monitor and titrate.
- Hepatic adjustment
- Requirements may fall; monitor glucose and titrate.
- Geriatric
- Conservative titration; higher hypoglycaemia risk.
- Max dose
- No fixed maximum — titrated to glycaemic target
Pharmacokinetics
Onset
~1–2 h
Peak effect
Relatively peakless (6–8 h modest)
Duration
~12–24 h (dose-dependent)
Half-life
~5–7 h (apparent, albumin-buffered)
Bioavailability
~60% (subcutaneous)
Protein binding
~98% (albumin, by design)
Metabolism
Proteolytic degradation
Excretion
Catabolised; minimal intact renal
Contraindications
- Hypoglycaemia
- Hypersensitivity to insulin detemir/excipients
Side effects
Common
HypoglycaemiaInjection-site reactionsWeight gain (less than some insulins)Lipodystrophy
Serious
- Severe hypoglycaemia
- Severe hypersensitivity/anaphylaxis
- Hypokalaemia
Pregnancy & lactation
Pregnancy
Acceptable in pregnancy (data support use; individualise).
Lactation
Compatible (insulin not orally bioavailable to infant).
Drug interactions
Ciprofloxacin
Severe
Database
Drug interaction classified as: antagonism
Source: DDInter
Delafloxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Enoxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Gatifloxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Gemifloxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Grepafloxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Levofloxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Lomefloxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Moxifloxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Nalidixic Acid
Severe
Database
Clinical effect not specified
Source: DDInter
Norfloxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Gestational diabetes mellitus
FOGSI · Obstetrics & Gynaecology · 2023
Fluid and electrolyte management in diabetes
RSSDI · Endocrinology · 2025
Diabetes management during Ramadan
ADA · Endocrinology · 2025
Glucose monitoring in diabetes
RSSDI · Endocrinology · 2024
Type 2 diabetes in adults
RSSDI · Endocrinology · 2022
Other Long-acting basal insulin analogue drugs
Ask House about Insulin Detemir
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20